Product Images Pemetrexed

This document appears to be a chart or a graph without context or additional information. It is not possible to provide a meaningful description without further details.*

This is a table showing the survival probability of two chemotherapy treatments, Pemetrexed + Cisplatin (PC) and Gemcitabine + Cisplatin (GC), against different survival times measured in months. The numbers in the table do not provide enough context to infer more information beyond the survival rates at different time intervals.*

This is a clinical data table that displays the survival times of two chemotherapy treatments for an unspecified medical condition. The treatments are named Pemetrexed + Cisplatin (PC) and Gemcitabine + Cisplatin (GC), and they were tested on a group of patients for a duration of up to 24 months. The table provides the number of patients in each group along with the number of patients who survived each month.*

This is a survival probability chart that shows the survival time in months. It lists the number of individuals at risk at specific time intervals and their survival probability. The information is presented in a table format.*

The text provides survival probability data for patients over time, represented by the number of months. The data relates to two groups of patients receiving different treatments - Pemetrexed and Pacebo. The number of patients at risk is documented for each time period for each group, with the Pemetrexed group having a larger number of patients in each interval.*

This appears to be a graph or chart showing Survival Probability over time in months, but insufficient information is provided to give a more detailed description.*

This is a graph that shows the survival probability of patients who were treated with Pemetrexed + Cisplatin (PC) and with Cisplatin alone. The x-axis shows the survival time in months and the y-axis shows the number of patients who survived. The graph shows that patients who received Pemetrexed + Cisplatin had a higher survival probability than those who received Cisplatin alone.*

This is a description for a medication with the brand name "HL220029". It is a single-dose vial medication to be used for intravenous infusion after dilution. The medication comes in a 25mg/mL dosage and should be discarded unused. There is a warning that it is a hazardous drug and should be stored refrigerated between 2-8°C. The recommended dosage is to be determined by the prescribing information. The medication is distributed by Hospira Inc. located in Lake Forest, IL, USA. The lot number is HL220029, and the expiration date is not available.*

This is a description of a drug called Pemetrexed, which is a form of chemotherapy used to treat cancer. It is contained in a vial of 4ml and should be stored refrigerated between 2°C and 8°C. The drug should be diluted with 0.9% Sodium Chloride Injection before use and administered as an infusion within 24 hours after dilution. Any unused portion should be discarded as it is a hazardous drug. The dosing information is available in the prescribing information, and the drug is made by Zydus Hospira Oncology Private Ltd.*

This appears to be a description of a medication called Pemetrexed, which is an injection medication administered intravenously after dilution. It is important to note that the drug is considered hazardous and should be handled with care. The medication comes in a 20mL single-dose vial and must be refrigerated at 2-8°C. Once diluted with 0.9% Sodium Chloride Injection, USP, the solution should also be stored refrigerated at 2-8°C and used within 24 hours of dilution. The dosage should be determined based on the prescribing information. The manufacturer of the medication is Zydus Hospira Oncology Private Ltd, located in Ahmedabad, India, and the drug is distributed by Hospira, Inc in Lake Forest, IL.*

This is a description of a Pemetrexed Injection medication. It is in a single dose vial, and unused portions should be discarded. The injection is hazardous and must be refrigerated at 2°C to 8°C. The text mentions recommended dosages and instructions on dilution. The company manufacturing the injection is Hospira Inc. The lot number is marked as "X."*

This appears to be a medication label providing information about Pemetrexed, a drug used for intravenous infusion after dilution. It contains instructions for dilution and administration, recommended dosage, and storage information. The product is manufactured by Zydus Hospir Oncology Private Limited and distributed by Hospia Inc in Lake Forest, USA.*